-
Je něco špatně v tomto záznamu ?
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
S. Cohen, EA. Spencer, MT. Dolinger, DL. Suskind, K. Mitrova, O. Hradsky, MA. Conrad, JR. Kelsen, HH. Uhlig, C. Tzivinikos, P. Henderson, M. Wlazlo, L. Hackl, DS. Shouval, M. Bramuzzo, D. Urlep, C. Olbjørn, G. D'Arcangelo, G. Pujol-Muncunill, D....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
PubMed
39921898
DOI
10.1111/apt.70016
Knihovny.cz E-zdroje
- MeSH
- Crohnova nemoc * farmakoterapie MeSH
- dítě MeSH
- heterocyklické sloučeniny tricyklické * terapeutické užití MeSH
- indukce remise * metody MeSH
- lidé MeSH
- mladiství MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: There are scarce data available on upadacitinib in children with Crohn's disease (CD). AIM: To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD. METHODS: This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post-induction. The analysis of the primary outcome was based upon the intention-to-treat (ITT) principle. RESULTS: We included 100 children (median age 15.8 [interquartile range 14.3-17.2]). All were previously treated with biologic therapies including 89 with ≥ 2 biologics. At the end of the 8-week induction period, we observed clinical response, clinical remission and corticosteroid- and exclusive enteral nutrition-free clinical remission (CFR) in 75%, 56% and 52%, respectively. By the end of induction, 68% had achieved normalisation of C-reactive protein, and 58% had faecal calprotectin (FC) < 150 mcg/g. There was combined CFR and FC remission in 13/31 children with available data at 8 weeks (13% of the ITT population). AEs were recorded in 24 children; the most frequent was acne in 12. Two AEs (severe acne and hypertriglyceridemia) led to discontinuation of therapy. CONCLUSION: Upadacitinib is an effective induction therapy for refractory paediatric CD. Efficacy should be weighed against the potential risks of AEs.
Al Jalila Children's Specialty Hospital Dubai UAE
Biomedical Research Centre University of Oxford Oxford UK
Centre of Human Genetics University of Oxford Oxford UK
Children's Hospital Zagreb University of Zagreb Medical School Zagreb Croatia
Department of Paediatric and Adolescent Medicine Akershus University Hospital Lørenskog Norway
Department of Paediatric Gastroenterology Children's Hospital HUS Helsinki Finland
Department of Paediatrics University of Oxford Oxford UK
Department of Pediatrics 1 Medical University Innsbruck Innsbruck Austria
Department of Pediatrics School of Medicine Kyungpook National University Daegu Korea
Faculty of Medicine Technion Haifa Israel
Faculty of Medicine Technion Israel Institute of Technology Haifa Israel
Faculty of Medicine Tel Aviv University Tel Aviv Israel
Gastroenterology and Nutrition Unit Meyer Children's Hospital IRCCS Florence Italy
Institute for Maternal and Child Health IRCCS Burlo Garofolo Trieste Italy
Jenny Lind Children's Hospital Norfolk and Norwich University Hospitals Norwich UK
Norwich Medical School University of East Anglia Norwich UK
Pediatric Department Children's Hospital Vittore Buzzi University of Milan Milan Italy
Pediatric Gastroenterology Unit Emek Medical Centre Afula Israel
Pediatric Hepatology Gastroenterology and Transplantation ASST Papa Giovanni XXIII Bergamo Italy
Translational Gastroenterology Unit University of Oxford Oxford UK
University of Helsinki Helsinki Finland
University of Washington Medical School Seattle Washington USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009352
- 003
- CZ-PrNML
- 005
- 20250429135015.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/apt.70016 $2 doi
- 035 __
- $a (PubMed)39921898
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cohen, Shlomi $u Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- 245 10
- $a Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study / $c S. Cohen, EA. Spencer, MT. Dolinger, DL. Suskind, K. Mitrova, O. Hradsky, MA. Conrad, JR. Kelsen, HH. Uhlig, C. Tzivinikos, P. Henderson, M. Wlazlo, L. Hackl, DS. Shouval, M. Bramuzzo, D. Urlep, C. Olbjørn, G. D'Arcangelo, G. Pujol-Muncunill, D. Yogev, B. Kang, M. Gasparetto, C. Rungoe, KL. Kolho, I. Hojsak, L. Norsa, F. Rinawi, N. Sansotta, RM. Rimon, M. Granot, L. Scarallo, E. Trindade, MV. Rodríguez-Belvís, D. Turner, A. Yerushalmy-Feler
- 520 9_
- $a BACKGROUND: There are scarce data available on upadacitinib in children with Crohn's disease (CD). AIM: To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD. METHODS: This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post-induction. The analysis of the primary outcome was based upon the intention-to-treat (ITT) principle. RESULTS: We included 100 children (median age 15.8 [interquartile range 14.3-17.2]). All were previously treated with biologic therapies including 89 with ≥ 2 biologics. At the end of the 8-week induction period, we observed clinical response, clinical remission and corticosteroid- and exclusive enteral nutrition-free clinical remission (CFR) in 75%, 56% and 52%, respectively. By the end of induction, 68% had achieved normalisation of C-reactive protein, and 58% had faecal calprotectin (FC) < 150 mcg/g. There was combined CFR and FC remission in 13/31 children with available data at 8 weeks (13% of the ITT population). AEs were recorded in 24 children; the most frequent was acne in 12. Two AEs (severe acne and hypertriglyceridemia) led to discontinuation of therapy. CONCLUSION: Upadacitinib is an effective induction therapy for refractory paediatric CD. Efficacy should be weighed against the potential risks of AEs.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a Crohnova nemoc $x farmakoterapie $7 D003424
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a indukce remise $x metody $7 D012074
- 650 12
- $a heterocyklické sloučeniny tricyklické $x terapeutické užití $7 D006575
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a dítě $7 D002648
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Spencer, Elizabeth A $u Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA $1 https://orcid.org/0000000267871164
- 700 1_
- $a Dolinger, Michael T $u Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA $1 https://orcid.org/0000000290234948
- 700 1_
- $a Suskind, David L $u University of Washington Medical School, Seattle, Washington, USA $1 https://orcid.org/0000000235245150
- 700 1_
- $a Mitrova, Katarina $u Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000218363745
- 700 1_
- $a Hradsky, Ondrej $u Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Conrad, Máire A $u Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 700 1_
- $a Kelsen, Judith R $u Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 700 1_
- $a Uhlig, Holm H $u Translational Gastroenterology Unit, University of Oxford, Oxford, UK $u Biomedical Research Centre, University of Oxford, Oxford, UK $u Department of Paediatrics, University of Oxford, Oxford, UK $u Centre of Human Genetics, University of Oxford, Oxford, UK $1 https://orcid.org/0000000261117355
- 700 1_
- $a Tzivinikos, Christos $u Al Jalila Children's Specialty Hospital, Dubai, UAE
- 700 1_
- $a Henderson, Paul $u Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, Scotland, UK $1 https://orcid.org/0000000336346428
- 700 1_
- $a Wlazlo, Magdalena $u Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Hackl, Lukas $u Department of Pediatrics I, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Shouval, Dror S $u Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva, Israel $u Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel $1 https://orcid.org/0000000159802954
- 700 1_
- $a Bramuzzo, Matteo $u Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy
- 700 1_
- $a Urlep, Darja $u Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Olbjørn, Christine $u Department of Paediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway
- 700 1_
- $a D'Arcangelo, Giulia $u Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza-University of Rome, Rome, Italy
- 700 1_
- $a Pujol-Muncunill, Gemma $u Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain
- 700 1_
- $a Yogev, Dotan $u The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
- 700 1_
- $a Kang, Ben $u Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea $1 https://orcid.org/0000000285169803
- 700 1_
- $a Gasparetto, Marco $u Jenny Lind Children's Hospital, Norfolk and Norwich University Hospitals, Norwich, UK $u Norwich Medical School, University of East Anglia, Norwich, UK
- 700 1_
- $a Rungoe, Christine $u Department of Paediatric and Adolescence Medicine, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark
- 700 1_
- $a Kolho, Kaija-Leena $u Department of Paediatric Gastroenterology, Children's Hospital HUS, Helsinki, Finland $u University of Helsinki, Helsinki, Finland $1 https://orcid.org/0000000191708415
- 700 1_
- $a Hojsak, Iva $u Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia
- 700 1_
- $a Norsa, Lorenzo $u Pediatric Department, Children's Hospital Vittore Buzzi, University of Milan, Milan, Italy $1 https://orcid.org/0000000333222921
- 700 1_
- $a Rinawi, Firas $u Pediatric Gastroenterology Unit, Emek Medical Centre, Afula, Israel $u Faculty of Medicine Technion, Haifa, Israel $1 https://orcid.org/0000000176345310
- 700 1_
- $a Sansotta, Naire $u Pediatric Hepatology, Gastroenterology and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy $1 https://orcid.org/0000000287997266
- 700 1_
- $a Rimon, Ramit Magen $u Pediatric Gastroenterology & Nutrition Institute, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Israel Institute of Technology, Haifa, Israel $u Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
- 700 1_
- $a Granot, Maya $u Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel $u Pediatric Gastroenterology Unit, Edmond & Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel $1 https://orcid.org/0000000215535847
- 700 1_
- $a Scarallo, Luca $u Gastroenterology and Nutrition Unit, Meyer Children's Hospital IRCCS, Florence, Italy
- 700 1_
- $a Trindade, Eunice $u Pediatric Gastroenterology and Nutrition Unit, Centro Hospitalar Universitário São João, Porto, Portugal
- 700 1_
- $a Rodríguez-Belvís, Marta Velasco $u Department of Pediatric Gastroenterology and Nutrition, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
- 700 1_
- $a Turner, Dan $u The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, the Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel $1 https://orcid.org/000000015160868X
- 700 1_
- $a Yerushalmy-Feler, Anat $u Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- 773 0_
- $w MED00009085 $t Alimentary pharmacology & therapeutics $x 1365-2036 $g Roč. 61, č. 8 (2025), s. 1372-1380
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39921898 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135010 $b ABA008
- 999 __
- $a ok $b bmc $g 2310998 $s 1246433
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 61 $c 8 $d 1372-1380 $e 20250208 $i 1365-2036 $m Alimentary pharmacology & therapeutics $n Aliment Pharmacol Ther $x MED00009085
- LZP __
- $a Pubmed-20250415
